Alkermes to Present at Upcoming Investor Conferences

Alkermes (Nasdaq: ALKS) announced that management will participate in fireside chats at two upcoming healthcare investor conferences in November 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2026 - 04:00 PM EST

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.

Stifel 2026 Healthcare Conference
Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT)

Jefferies Global Healthcare Conference in London
Date/Time: Fireside chat on Wednesday, Nov. 18, 2026 at 11:30 a.m. ET (4:30 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a leadership position in orexin biology and is advancing a portfolio of investigational orexin 2 receptor agonists for narcolepsy, idiopathic hypersomnia and other psychiatric and neurological disorders, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.